SCHEMBL19974150

SCHEMBL19974150

CCOC(=O)/C=C/C(=O)Nc1nc(C(=O)OC)cs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.58
MAPT P10636 3/20 0.58
HTT P42858 1/20 0.58
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
SMN1; SMN2 Q16637 8/20 0.52
GAA P10253 2/20 0.52
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
HPGD P15428 2/20 0.50
TSHR P16473 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPK1 P28482 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HSP90AA1 P07900 1/20 0.49
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
EGFR P00533 1/20 0.47
ACHE P22303 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30271562 0.88 MAPT (0.58) LMNAMAPTHTTCYP1A2CYP2C19
SCHEMBL19981418 0.84 MAPT (0.64) LMNAMAPTHTTCYP1A2CYP2C19
SCHEMBL19981463 0.78 MAPT (0.56) LMNAMAPTHTTSMN1; SMN2RAB9A
SCHEMBL22895511 0.78 CYP1A2 (0.69) LMNAMAPTCYP1A2CYP2C19SMN1; SMN2
SCHEMBL19981590 0.77 MAPT (0.60) LMNAMAPTHTTSMN1; SMN2MAPK1
SCHEMBL19981420 0.77 PARP1 (0.64) LMNAMAPTHTTSMN1; SMN2RAB9A
SCHEMBL19981467 0.75 MAPT (0.59) LMNAMAPTHTTSMN1; SMN2GAA
SCHEMBL4871149 0.74 CYP1A2 (0.76) LMNAMAPTCYP1A2CYP2C19SMN1; SMN2
SCHEMBL23647330 0.74 MAPT (0.56) LMNAMAPTHTTSMN1; SMN2RAB9A
SCHEMBL19981479 0.74 LMNA (0.64) LMNAMAPTHTTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512602-B1 INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF HSF PHARMACEUTICALS (CH) 2024-03-27 EP disclosed
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2023-03-07 US disclosed
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2021-07-22 US disclosed
EP-3512602-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF Pharmaceuticals (CH) 2019-07-24 EP disclosed
WO-2018050656-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF PHARMACEUTICALS (CH) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 LMNA 3549/4885MAPT 2930/4885HTT 1981/4885
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 LMNA 3549/4885MAPT 2930/4885HTT 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.